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Abstract: Background: CYP2D6 is a member of cytochrome P450 enzymes family which is involved in 
detoxification of a wide range of xenobiotics and drugs. Several genetic polymorphisms had been shown to affect its 
activity which may results in increased susceptibility to malignant disorders. Aim: to detect if there is specific 
cytochrome CYP2D6*4 genotype associated with hepatocellular carcinoma or hepatic cirrhosis among patients with 
hepatitis C.  Method: CYP2D6*4 genotyping was performed by polymerase chain reaction restriction fragment length 
polymorphism (PCR-RFLP). This study includes 23 patients with hepatic cirrhosis, 26 patients with HCC and normal 
19 subjects with matched age and sex. Results: The frequency of (Extensive metabolizers) EM genotype (wild type) 
was higher in HCC cases compared to cirrhotic patients and controls (76.8% versus 39.1% and 63.2%).The frequency 
of (intermediate metabolizers) IM genotype (heterozygous variant) was higher in cirrhotic cases compared to HCC 
patients and controls (52.2% versus 15.4% and 26.3 %). On contrary, the frequency of (poor metabolizers) PM 
genotypes (homozygous variant) was the lowest among HCC patients in comparison to cirrhotic patients and controls 
(3.8% vs 8.7% and 10.5% respectively). Higher frequency of IM and PM genotypes were observed in patients more 
than 45 years old in cirrhotic and malignant patients. Frequency of IM and PM were significantly higher in males than 
females in HCC patients (p=0.000). Frequency of p allele was higher in males than females and in older patients than 
younger patients in the three groups. Conclusions: These data indicate that PM CYP2D6*4 genotype has no role in 
development of HCC  and  IM genotype may have a role in developing hepatic cirrhosis, while higher frequency of 
EM genotype may contribute to the progression of  HCC in HCV-infected subjects 
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1. Introduction 
Hepatocellular carcinoma (HCC) is the sixth 
most prevalent malignant tumor worldwide and ranks 
the third as a cancer killer, causing more than half 
million deaths annually [1, 2]. Chronic hepatitis B and 
C viral infections have been well characterized to play 
a major role in the HCC etiology. The rates of HCV in 
Egypt are among the highest in the world, with a 
prevalence rate of up to 20% [3-5].  However, not all 
the individuals infected with HBV or HCV develop 
HCC, other risk factors including environment and 
genes may be involved in the multistage process of 
this complex disease [6]. Several studies have reported 
candidate cytochrome P450 (CYP) genes in which 
certain alleles are likely to be associated with cancer 
susceptibility [7]. 
The cytochrome P450 system is a group of 
enzymes that are responsible for metabolizing many 
endogenous and exogenous substances including 
xenobiotics such as procarcinogens, drugs, and 
environmental pollutant into more hydrophilic 
substances [8].  CYPs are encoded by at least 50 
different genes grouped in 10 families and sharing 
approximately 40% sequence homology and are 
mainly expressed in the liver. In humans, 90% of all of 
the drugs currently approved for clinical use are 
metabolized by one of seven CYP isoforms, CYP1A2, 
CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1 
and/or CYP3A4 [9,10]. As CYP-mediated 
bioactivation is an initial and obligatory step in 
chemical carcinogenesis, polymorphisms associated 
with altered enzyme activities may influence 
susceptibility to cancer, and specific combinations of 
alleles may ultimately provide the genetic fingerprint 
of one’s individual ability to respond to chemical and 
physical environmental agents, endobiotics 
compounds or infectious agents [11]. This means that 
altered levels of CYPs might be related to 
hepatocarcinogenesis.  It has also been shown that the 
genetic polymorphisms of CYP2E, CYP2D6 and 
CYP2C19 are associated with the development of 
HCC [12, 13].  
CYP2D6 is perhaps the most extensively studied 
polymorphically expressed drug metabolizing enzyme 
in humans and its polymorphism has a high clinical 
importance [14]. CYP2D6 isoform metabolizes more 
than 25% of most common drugs [15]. The CYP2D6 
gene is localized on chromosome 22q13.1. The locus 
contains two neighboring pseudogenes, CYP2D7 and 
CYP2D8. The presence of the highly similar closely 
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located pseudogenes carrying detrimental mutations 
have through, for example, unequal crossover 
reactions led to the formation of many of the variant 
CYP2D6 alleles, which most commonly encode 
defective gene products [14] . As a result of the 
presence of more than 70 allelic variants of CYP2D6 
gene [16], metabolism and excretion rates of drugs 
vary between individuals, from extremely slow to 
ultra-fast. Different phenotypes can be distinguished: 
poor metabolizers (PM) lack the functional enzyme; 
intermediate metabolizers (IM) carry 2 different 
alleles, leading to partial activity; efficient 
metabolizers (EM) have 2 normal alleles; efficient 
intermediate metabolizers (EIM) are heterozygous for 
1 deficient allele; and ultra-rapid metabolizers (UM) 
have multiple gene copies [14] . The most frequent 
inactivating mutation among Caucasians is the splice 
site G1934A transition (CYP2D6*4 allele) causes a 
truncated protein. G to A transition at the 
intron3/exon4 boundary of the CYP2D6 gene leads to 
incorrect splicing of mRNA resulting in a frame shift 
and premature termination [17,18 ] . This allele was 
previously called CYP2D6B and accounts for more 
than 70% of all the inactivating alleles in Caucasian 
populations [19]. This mutation result in decreased or 
lack of CYP2D6 isoenzyme activity, leading to PM 
phenotype [20] , increased risk for adverse side effects 
or therapeutic failure following drug treatment [21] 
and deficient hydroxylation of several classes of 
commonly used drugs, environmental toxic chemicals, 
and endogenous substances[22]. 
The aim of this study was to detect if there is 
specific cytochrome CYP2D6*4 genotype associated 
with hepatocellular carcinoma or hepatic cirrhosis 
among patients with hepatitis C. 
 
2. Material and Methods: 
Patients: 
A total of 49 anti-HCV positive patients recruited 
from gastroenterology unit of Internal Medicine 
department, Assiut University, Assiut , Egypt  were 
included in the study; 23 patients with liver cirrhosis 
and 26 patients with hepatocellular carcinoma. 
Nineteen healthy volunteers with matched age and sex 
were included in the study. Liver cirrhosis was 
diagnosed by clinical manifestation (including 
coagulopathy, hypoalbuminemia, abnormal liver 
function tests, haematologic evidence of 
hypersplenism, ascites, jaundice and portal 
hypertension with or without variceal bleeding), 
histological findings of liver biopsy and/or abdominal 
ultrasonography. The diagnosis of HCC was 
confirmed by a pathological examination or alfa-
fetoprotein (AFP) elevation (>400 ng/ml) combined 
with positive imaging (Magnetic resonance imaging, 
MRI and/or computerized tomography, CT) The 
control subjects had no history of any kind of cancer at 
the time of ascertainment. All subjects gave their 
informed consent to participate in this study. 
Methods: 
Eight ml venous blood was collected and divided 
into: 3ml in tube containing EDTA (ethylene diamine 
tetra-acetic acid) for complete blood count and DNA 
isolation, 1.8 ml in tube containing Na citrate for 
prothrombin time, concentration and INR and the 
remaining blood were collected in plain tubes. The 
samples were centrifuged within 30 minutes at 
3000rpm for 10 minutes and the serum samples then 
collected and divided into aliquots and stored at-70oC 
for further analysis.           
Liver function tests were assayed on BME 
Hitachi 911 auto-analyzer. Serum AFP was measured 
using chemo luminescence assay on IMMULIT 1000 
and specific assay kits (Siemens Lot. No LAPI 0060). 
Serum HBV markers, antibodies to hepatitis C virus 
were detected by commercially available micro 
particle enzyme immunoassay kits (AXSYM, Abbott 
Laboratories, Germany). 
Cytochrome P450-2D6*4 genotyping: 
Genotyping of CYP2D6*4 gene was performed 
by polymerase chain reaction and restriction fragment 
length polymorphism (PCR-RFLP) technique 
according to the method described by Lee et al.[23] 
DNA isolation was performed by QIAamp DNA mini 
kit. Cytochrome P450-2D6*4 gene detection was 
performed by PCR using a set of primer sequences 
which was designed by Schur et al. [24] containing 
the site of the polymorphism (G-to-A transition at 
position 1934A) as follow: the forward primer 5’-
GCCTTCGCCAACCACTCCG-3’ and the reverse 
primer: -5'-AAATCCTGCTCTTCCGAGGC-3'. A 
total 25 μl reaction volume for PCR amplification 
included, 12.5μl of 2xGo Taq Green PCR Master Mix 
(Promega Corporation, US), 2μl of each forward and 
reverse primers, 5μl template DNA and completed 
with nuclease- free water to 25μl. The amplification 
profile was as follow ( denaturation at 95ºC for 4 
minutes, 30 cycles of: 94°C for 1 minute then ,60ºC 
for 1 minute then 72ºC for 1.5 minutes and final 72ºC 
for10 minutes). In parallel with the samples, negative 
controls containing no DNA were run .The product of 
PCR amplification were subjected to agarose gel 
electrophoresis using 1.8 % agarose gel containing  
ethedium bromide for one hour at 100 volts (355 base 
pair PCR fragment was indicative of the presence of 
the gene).   
Digestion of the amplified product by Mva-1 
restriction enzyme: 10 µl of the PCR amplified 
product was incubated with 0.2µl (2 units) of the 
restriction endonuclease Mva-1 enzyme, 2.0µl of 
appropriate buffer (50 mM tris HCL, 100m M NaCl, 
10 mM EDTA, 1mM dithiothreitol, pH 7.5 at 37ºC) 
and 7.8 µl of DNA/RNA free water at 37 oC for 4 
hours. The digested products were electrophoresed on  
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2% Agarose gel containing Ethidium Bromide. Then 
the gel was visualized on an UV light for genotyping. 
Normal allele of CYP2D6*4 (EM) produces two 
fragments of 250 and 105 bp after digestion with Mva-
1 restriction enzyme. G to A transition at position 
1934 abolishes the restriction site and a fragment of 
355 bp is observed. Heterozygous individuals (IM) 
show normal allele (250, 105 bp) and one mutated 
allele of 355 bp and homozygous individuals (PM) 
showing 355 bp band. 
Statistical analysis: 
Data were statistically described in terms of 
range; mean ±standard deviation ±SD, frequencies 
(number of cases) and relative frequencies 
(percentages) when appropriate. SPSS Version 17.0 
(SPSS Inc., Chicago, IL) was used for all data 
analyses. Chi-square or Chi Square test were used for 
contrasts involving categorical variables. For 
comparisons involving continuous variables, the two-
sided two-sample Student t test, Welch Modified 
ANOVA were used in cases where the normal 
distribution assumption or equal variance assumptions 
were not viable. Odd Ratio (OR with its 95% CI was 
calculated for the occurrence of PM and IM between 
cases and controls) A probability value (p value) less 
than 0.05 was considered statistically significant. 
 
3. Results: 
Patient’s characteristics are summarized in table 
(1). In table (2) CYP2D6*4 genotyping data were 
combined to express 3 categories, as previously 
described: extensive (EM), intermediate (IM) and poor  
metabolizers (PM) , frequencies of 3 CYP2D6*4 
categories among healthy subjects were 63.2% for 
EM, 26.3% for IM and 10.5% for PM, in agreement 
with published data, Vineis  et al. [25]. Genotype 
distribution differed among the two patients groups; in 
particular, PM was reduced among HCC compared 
with cirrhosis patients (3.8 % vs. 8.7 %), however 
there was no statistical significant difference. This 
finding suggests that PM genotypes may behave as a 
protection factor in severe liver lesions. On the other 
hand, EM was significantly increased in HCC group in 
comparison to cirrhotic group (p=˂0.01). As an 
estimate for the relative risk, the odds ratio for EM 
genotype was 6.533 with a 95% confidence interval of 
1.807- 23.627. These data indicate a higher risk for 
HCC in individuals carrying the EM CYP2D6*4. 
When data was compared with respect to age of 
the patients, there was higher frequency of IM and PM 
observed in patients more than 45 years old in 
cirrhotic and malignant patients. However, frequency 
of EM was higher in patients less than 45 years old in 
cirrhotic, malignant and control groups. Frequency of 
p allele was higher in the three groups in individuals 
more than 45 years old (Table 3). 
When data was compared with respect to sex of 
the patients, there was higher frequency of IM and PM 
observed in males compared to females in cirrhotic 
and HCC group; however there was no statistical 
significant difference. Frequency of p allele was 
higher in males than females in the three groups 
(Table 4).  
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     EM= Extensive metabolizer, IM= Intermediate metabolizer, PM= Poor metabolizer, , * p-value <0.05 ,   * 
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4. Discussion: 
Carcinogenic process in patients with HCV-
associated liver disease, mainly cirrhosis, is thought to 
involve multiple steps, and many risk factors have 
been proposed. In the clinical setting some patients 
with HCV-associated cirrhosis progress to HCC, while 
others never develop HCC. Such a difference in 
progression to HCC is clinically important, and the 
factor(s) affecting this difference should be elucidated 
in such patients. However, this issue remains 
unsolved. One of the many risk factors is the patient’s 
capability to metabolize xenobiotics (including drug), 
because some xenobiotics play a role in inducing 
cancer as procarcinogen or carcinogen [7].  
 In the present study, Cirrhotic patients, HCC 
patients and healthy control subjects were compared 
with respect to genotype frequencies of CYP2D6*4, 
which have been suggested to alter the enzyme 
activity.  The frequency of mutation of the CYP2D6 
allele (PM) was lower in HCC patients than in 
cirrhotic patients or healthy subjects, however, no 
statistical significant difference was found. This 
finding was in agreement with the study of Agúndez 
et al. [26], who used the RFLP method and reported 
that the frequency of mutation of the CYP2D6 allele 
(PM) is lower in HCC patients than in cirrhotic 
patients or healthy subjects. They found no significant 
difference in the frequency of the CYP2D6 allele 
between the HCC patients and healthy controls. Also, 
Kimura et al. [27] found no significant differences 
between HCC patients and controls in the frequency of 
the allele. Another study was conducted by 
Mochizuki et al.  [7] who compared the frequencies 
of mutation of CYP2D6 allele in healthy subjects with 
HCC patients. They extracted the genetic polymorphic 
frequencies of CYP subtypes in healthy Japanese 
subjects from the review of Shimizu et al. [28] that 
summarized the data from many reports and compared 
the frequencies of mutant alleles in healthy subjects 
with HCC patients; they found no statistically 
significant differences in mutant alleles between the 
two groups.  On the contrary to our findings, Silvestri 
et al. [11] found an association between the CYP2D6 
polymorphism and cirrhosis in HCV patients and 
hepatomas in patients with chronic liver diseases. 
They examined the prevalence of various genotypes of 
CYP2D6 in four groups of patients with HCV: 
asymptomatic carriers, patients with active hepatitis, 
cirrhotic patients and patients with hepatoma.  
 CYP2D6 genotypes have an effect on liver 
disease progression as shown by the distribution of 
different genotypes according to the severity of liver 
lesions [11]. Several studies have shown that the 
extensive metabolizer (EM) phenotype is associated 
with increased risk of various cancers [29]]. The 
relationship of CYP2D6 genotypes with liver cancer 
has been explored by Agundez et al. [26] in a case-
control study that compared hospital controls and 
HCC patients with different etiologies. A significant 
association with risk was observed for high activity 
alleles. Our data confirmed these observations as the 
frequency of EM phenotype was significantly higher 
in HCC group than in cirrhotic group and normal 
control (76.8 % vs 39.1 and 63.2% %).The over-
representation of CYP2D6*4 EM among HCC 
patients can be explained in two ways: first, the 
CYP2D6*4 may mediate the activation of 
procarcinogenic agents present in environment. 
Second, the CYP2D6*4 gene may be in a linkage 
disequilibrium with the causative gene.  
It is noteworthy that patients carrying IM or PM 
genotype with less metabolic activity may not be able 
to respond to the treatment. Moreover, these patients 
when treated with normal amount of drug dose, the 
drug will accumulate in the body and ultimately turns 
into carcinogen. Alternately, if these patients were 
treated with lower drug doses, it might lead to drug 
resistance and poor prognosis. Hence these patients 
must be treated with caution [30]. In this study, IM 
genotype frequency was statistically significant higher 
in cirrhotic group than malignant group (52.2% vs 
15.4%). These facts suggested a role for IM 
CYP2D6*4 in hepatic disease severity and its 
deterioration toward cirrhosis.  
Ageing is the progressive accumulation of more 
or less random changes that lead to time-related loss 
of functional units e.g. nephrons, alveoli, or neurons. 
These time-related changes may explain partly the 
increased inter-individual variability occurring in drug 
disposition as people get older [31]. Investigations on 
the influence of ageing on phase I enzymes in humans 
have reported conflicting results. Indeed, a study 
conducted in 54 liver samples from healthy donors 
from 9 to 89 years did not show changes in 
microsomal protein content, total P450 or NADPH 
cytochrome P450 reductase activity with age. By 
contrast, another study carried out in 226 subjects with 
histopathologic changes of the liver revealed a 
significant decrease of 32% in total cytochrome P450 
content of liver biopsy samples in subjects >70 years 
as compared to young adults [32].  
In the current study, increased frequency of IM 
(55.6% and 16%) and PM (11.1% and 4% )  were 
observed in cirrhotic patients and HCC patients more 
than 45 years old respectively .In contrary to our 
findings, Sailaja et al. [33] demonstrated that, patients 
less than 20 years of age have increased frequency of 
IM (28.57%) and PM (4.76%) genotype with 
corresponding increase in P allele frequency. This 
difference in our results can be referred to the age 
groups of our patients as most of them were higher 
than 45 years old and nobody less than 20 years old.  
Also, the differences in the results obtained in 
previous researches can be explained by the inter-
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individual variability in xenobiotic metabolism and  
frequencies of these polymorphisms are variable in 
different populations due to different ethnic 
backgrounds, environment and lifestyle. 
In the current study, when data was compared 
with respect to sex of the patients, there was higher 
frequency of IM (55.5% and 18.1%) and PM (11.1% 
and 4.5%) observed in males compared to females in 
cirrhotic and HCC patients, with higher p allele 
frequency in males. The present study was in 
agreement with the study of the Sailaja et al. [33] who 
stated that P allele frequency was increased in male 




PM CYP2D6*4 genotype has no role in 
development of HCC but may behave as a protection 
factor int severe liver lesion. IM genotype may have a 
role in developing hepatic cirrhosis. The high activity 
allele (EM genotype) associated with HCC may 
contribute to the progression of HCC in HCV-infected 
subjects. CYP2D6*4 might serve as a genetic non-
invasive marker, enabling identification of HCV-
infected patients that are prone to develop cirrhosis or 
HCC early in the course of the infection.  
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